Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrylamide SCHEMBL3201102 | 1.00 | LMNA (0.39) | LMNATSHRALDH1A1FGFR4TP53 | |
| Triethylene Glycol SCHEMBL3199626 | 0.87 | LMNA (0.39) | LMNATSHRALDH1A1FGFR4TP53 | |
| Acrylamide SCHEMBL2259418 | 0.86 | LMNA (0.52) | LMNATSHRALDH1A1FGFR4THRB | |
| Acrylamide SCHEMBL6672038 | 0.86 | LMNA (0.52) | LMNATSHRALDH1A1FGFR4THRB | |
| Acrylamide SCHEMBL3211148 | 0.84 | LMNA (0.50) | LMNATSHRALDH1A1FGFR4 | |
| Acrylamide SCHEMBL3213985 | 0.84 | TSHR (0.50) | TSHRALDH1A1FGFR4TP53HIF1A | |
| SCHEMBL3199752 | 0.80 | LMNA (0.60) | LMNATHRBCA2 | |
| SCHEMBL3206613 | 0.80 | LMNA (0.60) | LMNATHRBCA2 | |
| Acrylamide SCHEMBL21777535 | 0.78 | TSHR (0.42) | TSHRALDH1A1FGFR4TP53HIF1A | |
| Acrylamide SCHEMBL28208642 | 0.78 | ALDH1A1 (0.42) | TSHRALDH1A1FGFR4TP53HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683041-B2 | Microgel particles for the delivery of bioactive materials | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-23 | — | — | US | disclosed |
| US-20060223776-A1 | Microgel particles for the delivery of bioactive materials | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-10-05 | — | — | US | disclosed |
| US-7056901-B2 | Microgel particles for the delivery of bioactive materials | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1490083-A1 | MICROGEL PARTICLES FOR THE DELIVERY OF BIOACTIVE MATERIALS | The Regents of the University of California (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20030211158-A1 | Microgel particles for the delivery of bioactive materials | UNITED STATES DEPARTMENT OF ENERGY | 2003-11-13 | — | — | US | disclosed |
| WO-2003082316-A1 | MICROGEL PARTICLES FOR THE DELIVERY OF BIOACTIVE MATERIALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030211158-A1 | Microgel particles for the delivery of bioactive materials | CTSE, CHMP4B, GAA | LMNA 519/4885TSHR 4770/4885ALDH1A1 2991/4885 |
| US-20060223776-A1 | Microgel particles for the delivery of bioactive materials | CTSE, CHMP4B, GAA | LMNA 519/4885TSHR 4770/4885ALDH1A1 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.